HAIXI PHARMA Allocates Idle Capital to Financial Products

Stock News

02/05

HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1136379883"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136379883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136379883?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136379883","market":"nz","top_or_hot":-1,"title":"HAIXI PHARMA Allocates Idle Capital to Financial Products","media":"Stock News","content":"<p>HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Allocates Idle Capital to Financial Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Allocates Idle Capital to Financial Products\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-02-05 16:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新藥","start_time":0,"source_url":"","article_id":"1136379883","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136379883","pubTimestamp":1770280827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159940":"金融","02637":"海西新药","BK1191":"制药"},"translate_title":"海西药业闲置资金配置理财产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159940":1,"02637":1},"content_text":"HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}